Press release

Katie Eyestone, Kathleen Fairall, and Vanessa Watson Join Elligo Health Research

businesswire,
0
Sponsored by Businesswire

Elligo Health Research is proud to welcome Vice President, Healthcare Partnerships Katie Eyestone, Chief People Officer Kathleen Fairall, and Vice President, Practice Success Vanessa Watson to its leadership team. The three women bring valuable and varied skills to their roles while increasing the gender diversity of the leadership team.

  • Vice President, Healthcare Partnerships Katie Eyestone, previously chief transformation officer at HSS, will continue to shape and grow Elligo’s network of healthcare partner organizations.
  • Chief People Officer Kathleen Fairall, previously principal at Act III Consulting, will oversee and execute the human resources strategy in support of the overall business plan and strategic direction of the organization.
  • Vice President, Practice Success Vanessa Watson, previously director of site communications and strategic development at Optimal Research, will lead the building and maintenance of practice and system relationships within the Elligo healthcare network, as well as develop and execute a research business strategy.

“We are excited to welcome Katie, Kathleen, and Vanessa to Elligo,” said John Potthoff, Ph.D., CEO of Elligo. “Each brings a depth and breadth of experience to their roles that will add significant perspective, insight, and future planning guidance as Elligo works to ensure that all patients have access to clinical trials as a care option.”

About Elligo Health Research®

Elligo Health Research, a healthcare-enabling research organization, uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. Powered by our Goes Direct® approach and novel IntElligo® Research Stack clinical technology, our team provides access to the best healthcare experts, patients, and research technologies. We engage physicians and patients who otherwise would not participate in clinical research and accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. Learn more at elligodirect.com.